| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $40.0M | -9.0% | +20.2% |
| SG&A Expense | $5.9M | +49.6% | +34.8% |
| Operating Income | -$45.9M | +4.2% | -21.9% |
| Net Income | -$42.2M | +3.6% | -22.2% |
| EPS (Basic) | -$0.49 | +3.9% | +18.3% |
| EPS (Diluted) | -$0.49 | +3.9% | +18.3% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $35.3M | -32.8% | -1.7% |
| Short-term Investments | $293.7M | -5.1% | +64.2% |
| Current Assets | $334.3M | -9.1% | +53.4% |
| Total Assets | $352.5M | -7.7% | +53.1% |
| Current Liabilities | $41.7M | +25.6% | +35.7% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$108.4M | — | — |
| Capital Expenditures | $0 | — | — |
| Investing Cash Flow | $6.4M | — | — |
| Financing Cash Flow | -$2.3M | — | — |
| Free Cash Flow | -$108.4M | — | — |
| $45.0M |
| +22.3% |
| +43.8% |
| Stockholders' Equity | $307.5M | -10.9% | +54.6% |